Literature DB >> 33276673

Immunological Distinctions between Acellular and Whole-Cell Pertussis Immunizations of Baboons Persist for at Least One Year after Acellular Vaccine Boosting.

Leah E Cole1, Jinrong Zhang1, Kristl M Pacheco1, Philippe Lhéritier2, Natalie G Anosova1, Julie Piolat2, Lingyi Zheng3, Nathalie Reveneau2.   

Abstract

While both whole-cell (wP) and acellular pertussis (aP) vaccines have been highly effective at reducing the global pertussis disease burden, there are concerns that compared to wP vaccination, the immune responses to aP vaccination may wane more rapidly. To gain insights into the vaccine elicited immune responses, pre-adult baboons were immunized with either aP or wP vaccines, boosted with an aP vaccine, and observed over a nearly two-year period. Priming with a wP vaccine elicited a more Th17-biased response than priming with aP, whereas priming with an aP vaccine led to a more Th2-biased response than priming with wP. These differences were maintained after aP vaccine boost immunizations. Compared to aP, animals primed with a wP vaccine exhibited greater numbers of pertussis specific memory B cells. While aP and wP vaccine priming initially elicited similar levels of anti-pertussis toxin antibody, titers declined more rapidly in aP vaccine primed animals leading to a 4-fold difference. Both wP and aP vaccine immunization could induce serum bactericidal activity (SBA); however, only one wP vaccine immunization was required to elicit SBA while multiple aP vaccine immunizations were required to elicit lower, less durable SBA titers. In conclusion, when compared to aP vaccine, priming with wP vaccine elicits distinct cellular and humoral immune responses that persist after aP vaccine boosting.

Entities:  

Keywords:  acellular pertussis vaccine; baboon model; immunological profile; pertussis; whole cell pertussis vaccine

Year:  2020        PMID: 33276673      PMCID: PMC7761625          DOI: 10.3390/vaccines8040729

Source DB:  PubMed          Journal:  Vaccines (Basel)        ISSN: 2076-393X


  48 in total

Review 1.  The pertussis enigma: reconciling epidemiology, immunology and evolution.

Authors:  Matthieu Domenech de Cellès; Felicia M G Magpantay; Aaron A King; Pejman Rohani
Journal:  Proc Biol Sci       Date:  2016-01-13       Impact factor: 5.349

2.  Waning Tdap Effectiveness in Adolescents.

Authors:  Nicola P Klein; Joan Bartlett; Bruce Fireman; Roger Baxter
Journal:  Pediatrics       Date:  2016-02-05       Impact factor: 7.124

3.  Priming with whole-cell versus acellular pertussis vaccine.

Authors:  Juventila Liko; Steve G Robison; Paul R Cieslak
Journal:  N Engl J Med       Date:  2013-02-07       Impact factor: 91.245

4.  Airborne transmission of Bordetella pertussis.

Authors:  Jason M Warfel; Joel Beren; Tod J Merkel
Journal:  J Infect Dis       Date:  2012-07-17       Impact factor: 5.226

5.  The impact of past vaccination coverage and immunity on pertussis resurgence.

Authors:  Matthieu Domenech de Cellès; Felicia M G Magpantay; Aaron A King; Pejman Rohani
Journal:  Sci Transl Med       Date:  2018-03-28       Impact factor: 17.956

6.  Boosting Teenagers With Acellular Pertussis Vaccines Containing Recombinant or Chemically Inactivated Pertussis Toxin: A Randomized Clinical Trial.

Authors:  Geraldine Blanchard Rohner; Olga Chatzis; Pailinrut Chinwangso; Marie Rohr; Stéphane Grillet; Carole Salomon; Barbara Lemaître; Pitchaya Boonrak; Saranath Lawpoolsri; Elizabeth Clutterbuck; Indrajeet Kumar Poredi; Wassana Wijagkanalan; Jane Spiegel; Hong Thai Pham; Simonetta Viviani; Claire-Anne Siegrist
Journal:  Clin Infect Dis       Date:  2019-03-19       Impact factor: 9.079

7.  Randomized study of immune responses to two Tdap vaccines among adolescents primed with DTaP and comparison with results among adolescents primed with DTwP.

Authors:  Michael D Decker; David P Greenberg; David R Johnson; Vitali Pool
Journal:  Vaccine       Date:  2019-07-10       Impact factor: 3.641

8.  A controlled trial of a two-component acellular, a five-component acellular, and a whole-cell pertussis vaccine.

Authors:  L Gustafsson; H O Hallander; P Olin; E Reizenstein; J Storsaeter
Journal:  N Engl J Med       Date:  1996-02-08       Impact factor: 91.245

9.  A phase I, randomized, controlled, dose-ranging study of investigational acellular pertussis (aP) and reduced tetanus-diphtheria-acellular pertussis (TdaP) booster vaccines in adults.

Authors:  Geert Leroux-Roels; Maria Lattanzi; Claudia Dovali Solis; Mario Contorni; Marco Costantini; Luca Moraschini; Monia Bardelli; Sylvie Bertholet; Erica Borgogni; Francesca Buricchi; Rocco Cantisani; Elisa Faenzi; Oretta Finco; Rosanna Leuzzi; Mariagrazia Pizza; Domenico Rosa; Francesca Schiavetti; Anja Seubert; Fabiana Spensieri; Gianfranco Volpini; Luisanna Zedda; Giuseppe Del Giudice; Ilaria Galgani
Journal:  Hum Vaccin Immunother       Date:  2017-11-27       Impact factor: 3.452

10.  A cocktail of humanized anti-pertussis toxin antibodies limits disease in murine and baboon models of whooping cough.

Authors:  Annalee W Nguyen; Ellen K Wagner; Joshua R Laber; Laura L Goodfield; William E Smallridge; Eric T Harvill; James F Papin; Roman F Wolf; Eduardo A Padlan; Andy Bristol; Michael Kaleko; Jennifer A Maynard
Journal:  Sci Transl Med       Date:  2015-12-02       Impact factor: 17.956

View more
  2 in total

1.  Göttingen Minipigs as a Model to Evaluate Longevity, Functionality, and Memory of Immune Response Induced by Pertussis Vaccines.

Authors:  Céline Vaure; Véronique Grégoire-Barou; Virginie Courtois; Emilie Chautard; Cyril Dégletagne; Yuanqing Liu
Journal:  Front Immunol       Date:  2021-03-17       Impact factor: 7.561

2.  Intranasal inoculation with Bordetella pertussis confers protection without inducing classical whooping cough in baboons.

Authors:  Thibaut Naninck; Vanessa Contreras; Loïc Coutte; Sébastien Langlois; Aurélie Hébert-Ribon; Magali Pelletier; Nathalie Reveneau; Camille Locht; Catherine Chapon; Roger Le Grand
Journal:  Curr Res Microb Sci       Date:  2021-10-09
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.